Outcome of the Board Meeting held today on 03rd February, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals' board approved its Q3 FY26 standalone unaudited results. Revenue from operations for Q3 rose to Rs 43.02 crore, up 16.6% year-on-year from Rs 36.89 crore. For the 9 months ended December 2025, revenue grew 12.2% YoY to Rs 124.11 crore. However, Q3 profit after tax slipped to Rs 5.93 crore vs Rs 6.51 crore in Q3 FY25, an 8.9% YoY decline, while 9M PAT was largely flat at Rs 23.89 crore (+1.5% YoY). Profitability in Q3 was hit by a sharp jump in employee benefit expenses (up ~35% YoY), which the company attributes to additional provisions required under the new Labour Codes on Wages 2019. The auditor issued an unqualified (clean) limited review report with no qualifications.
Operational momentum looks healthy on the revenue side, but one-time wage provisions under the new Labour Codes compressed Q3 margins and pulled down quarterly earnings. Investors should track margin recovery in Q4 once the provision impact lapses.